Pre-market Gainers in Focus: MediciNova, Inc. (NASDAQ:MNOV), Sigma Designs Inc. (NASDAQ:SIGM), KEYW Holding Corp. (NASDAQ:KEYW), Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO)

MediciNova, Inc. (NASDAQ:MNOV) a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced positive results from a study that examined the potential clinical efficacy of MN-001 (tipelukast) for the treatment of pulmonary fibrosis. MediciNova, Inc. (NASDAQ:MNOV) stock opened today at $2.12 and is currently trading at $2.03.

Shares of Sigma Designs Inc. (NASDAQ:SIGM) popped 5% in pre-market trading Thursday after Needham upgraded the digital TV chip technologist from hold to buy. Sigma Designs Inc. (NASDAQ:SIGM) stock opened at $4.26, in current trading session and currently is at $4.51, by gaining 15.05%. The 52 week range of $3.28 – $6.70. Company’s market capitalization is 155.39 million.

The KEYW Holding Corporation (NASDAQ:KEYW) Hexis Cyber Solutions, Inc. (Hexis), a wholly-owned subsidiary of The KEYW Holding Corporation (Nasdaq:KEYW), today announced that a leading U.S. government agency has taken an initial delivery of its next-generation threat investigation and automated malware removal solution, HawkEye G, to deliver advanced threat detection and automated malware removal. KEYW Holding Corp. (NASDAQ:KEYW) stock is currently trading at $11.06. The EPS of the stock is -0.31. Company’s market capitalization is 413.87 million.

Jack Lief, co-founder, president and CEO of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), said the prescription growth for Belviq, a weight-loss drug has been tremendous. It is FDA-approved and promotional activity from Eisai is boosting in sales, he said. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened the session at $6.44, and now is at $6.45. The 52 week range of the Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock remained $4.05 – $9.05 and the day range was $6.31 – $6.46.

Halozyme Therapeutics Inc. (NASDAQ:HALO) was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock opened today at $9.67 and is currently trading at $9.74. The stock showed a positive weekly performance of 16.21%.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *